Acute ischaemic stroke trial
In a 2018 report of 110 post-stroke patients in early and late rehabilitation, intranasal Semax was associated with increased plasma BDNF, improved motor performance, and improved functional-independence scores (Barthel Index) relative to comparison.
- Study type
- Human trial
- Population
- 110 post-stroke patients (43 men, 67 women) in early and late rehabilitation groups
- Source
- 1 Gusev et al., 2018
Limitation: The 2018 report does not state whether patients were randomised or blinded.
Limitations in full
The 2018 report does not state whether patients were randomised or blinded. An earlier study from the same research programme compared 30 Semax-treated patients with 80 patients on conventional therapy; randomisation is not stated there either. Single research programme.